Results 181 to 190 of about 41,710 (302)

Dipeptidyl Peptidase-4 Inhibitors

Circulation Journal, 2013
openaire   +3 more sources

Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini, Hassan Valadbeigi, Seyedeh Mahdieh Khoshnazar, Saeed Khoshnood, Shahab Falahi, Delsuz Rezaee, Ali Hematian, Mohammad Hossein Haddadi   +7 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis. [PDF]

Int J Mol Sci, 2022
Hung CT, Chang YL, Wang WM.
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4837-4846, June 2026.
ABSTRACT Aims To evaluate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation and the risk of hepatic decompensation compared with dipeptidyl peptidase 4 inhibitors (DPP4is) in a racially and ethnically diverse cohort of adults with Type 2 diabetes.
Inyoung Hwang, Yun Kim, Sang Won Lee
wiley   +1 more source

Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study. [PDF]

Int J Endocrinol
Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T.   +10 more
europepmc   +1 more source

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients. [PDF]

Case Rep Dermatol, 2022
Balighi K, Heidari S, Kavyani M, Kamyab Hesari K, Tootoonchi N.   +4 more
europepmc   +1 more source

Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.
ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun, Seohyun Kim, In‐Kyung Jeong, Jae Hyeon Kim   +3 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. [PDF]

Clin Pharmacokinet
Liu W, Yang K, Lin Y, Lu C, Liu J, Zhou H, Wang J, Zhang T, Yao L, Qi H, Zhang X, Jia R, Li X, Jing S.   +13 more
europepmc   +1 more source

Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5058-5067, June 2026.
ABSTRACT Aims The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real‐world clinical settings. Materials and Methods This retrospective, multi‐centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023.
Taweesak Wannachalee, Pimjai Anthanont, Supamas Sirisreetreerux, Gurudutt Nayak, Woralak Chumchujan, Yodying Iamsudjai, Supawan Buranapin   +6 more
wiley   +1 more source

Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence. [PDF]

World J Diabetes, 2021
Roy A, Sahoo J, Narayanan N, Merugu C, Kamalanathan S, Naik D.   +5 more
europepmc   +1 more source